Eton Pharmaceuticals to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
Eton Pharmaceuticals, Inc. (Nasdaq: ETON) announced its plan to release third quarter 2022 financial results on November 10, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eton Pharmaceuticals, Inc. (Nasdaq: ETON) announced its plan to release third quarter 2022 financial results on November 10, 2022. The management will host a conference call at 4:30 p.m. ET to discuss the results, with live audio accessible via the company's investor relations website. Participants are required to register for dial-in details, enhancing security and streamlining access. Eton specializes in developing treatments for rare diseases and currently has three FDA-approved products, along with several candidates in late-stage development.
Positive
- Three FDA-approved products: ALKINDI SPRINKLE®, Carglumic Acid tablets, and Betaine Anhydrous for Oral Solution.
- Three late-stage pipeline candidates: dehydrated alcohol injection, ZENEO® hydrocortisone autoinjector, and ET-400.
- Royalties from three additional FDA-approved products and potential milestone payments.
Negative
- None.
Details
News Market Reaction – ETON
The recorded move for ETON in the trading session of this news was +2.39%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DEER PARK, Ill., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2022 financial results on Thursday, November 10, 2022. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT).
Register* (Audio Only) Click Here
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
The live webcast can be accessed on the investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
* Beginning this quarter, conference call participants should register to obtain their dial-in and passcode details. The new, streamlined process improves security and eliminates wait times when joining the call. Please be sure to register using a valid email address.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has three FDA approved products in ALKINDI SPRINKLE®, Carglumic Acid tablets, and Betaine Anhydrous for Oral Solution, and three late-stage pipeline candidates under development with dehydrated alcohol injection, ZENEO® hydrocortisone autoinjector, and ET-400. In addition, the Company receives royalties on three FDA-approved products and is entitled to receive milestone payments on other products.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.